HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 24, No 12, December 2019 – Precision Medicine for Brain Tumours       » First Alzheimer's drug to be approved in 17 years holds promise for treatment       » Tencent make medical information readily available to the public       » United States FDA approves first China-made cancer drug       » Value-Based Healthcare: A Paradigm Shift for Better Patient Outcomes       » Precision Agriculture for Future Nutritional Needs      
EYE ON CHINA
Gene-editing tool uses light to kill cancer cells
New technique can precisely alter or cut designated spot in genome

Chinese scientists recently designed a remote-controlled gene-editing platform using light, which can precisely target and kill cancer cells and offer revolutionary treatment for diseases including cancer, diabetes and Parkinson's disease.

A team led by Song Yujun, a professor at the College of Engineering and Applied Sciences at Nanjing University, designed the near-infrared (NIR) light-responsive nanocarrier for gene-editing tool CRISPR-Cas9 for cancer therapeutics, and the team published their findings in Science Advances.

"Using infrared light, the new technique can precisely alter or cut the designated spot in the genome, greatly improving the target effect of gene-editing tool," said Song. The strong penetration ability of infrared light provides possibilities for scientists to precisely control the gene editing tool, CRISPR-Cas9, in deep tissue.

The CRISPR-Cas9 technique allows genetic materials to be added, removed or altered at particular locations in the genome. But CRISPR-Cas9 is still a challenge to precision medicine worldwide due to its off-target effect and in some cases, may cause cancer in cells.

Off-target editing could result in serious consequences in cancer treatment, as it may cut or alter the wrong spot in the genome, thus killing healthy cells instead of cancerous ones.

In a notorious experiment that helped create the world's first gene-edited babies last year, He Jiankui, the scientist who conducted the experiment, used CRISPR-Cas9 to alter the CCR5 gene in twin baby girls. He was widely criticised as the technique cannot guarantee accurate excision of the gene.

The new technique developed by Song's team has been tested on mice with tumours, and the result found that the progression of tumours was gradually delayed on the mice that received the new technique for 20 days.

It was relatively easy to conduct the experiment on mice due to their small size, but the amount of light needed for humans is still uncertain.

China has tightened management on new biomedical technology after He's case, and a regulation on biomedical technology released in February states that high-risk clinical research projects including gene-editing technology must be approved by the health department of the State Council, and will have to pass both academic and ethics reviews.

Source: Global Times

Click here for the complete issue.

NEWS CRUNCH  
news Proteona awards grant to clinician-scientist for research in treatment selection of multiple myeloma
news Technology giant, Tencent Holdings Limited, promotes medical science and healthcare
news ECV2019 China Healthcare and Pharma Digital Innovation Summit Held Successfully in Shanghai — The "Highway" Era of Healthcare Digital Transformation
news Natural Extracts Innovated, Transformed and Diversely Laid Out to Embrace the Blue Ocean Market of Big Health
PR NEWSWIRE  
Asia Pacific Biotech News
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
October:
Disruptive Urban Farming — Microbes, Plasmids, and Recycling
November:
Evaluating cost effectiveness of genomic profiling
December:
Precision Medicine for Brain Tumours
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy